Current role of portal vein embolization/hepatic artery chemoembolization.
This article has reviewed indications, methods, and results of PVE and TACE for hepatobiliary tumors. PVE is applied mainly to increase the safety of major hepatic resection in patients with hilar cholangiocarcinoma, HCC, or metastatic liver tumors. Hepatic arterial embolization causes selective ischemia of the liver tumor and enhances the cytotoxicity of the chemotherapeutic agent administered concomitantly. A survival benefit of TACE in patients with unresectable or recurrent HCC has been demonstrated. The significance of preoperative TACE is still controversial. TACE is routinely performed before PVE in HCC patients.
Kokudo
Norihiro
N
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Makuuchi
Masatoshi
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001284:Atrophy; D001650:Bile Duct Neoplasms / Q000601:surgery / Q000628:therapy; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D018281:Cholangiocarcinoma / Q000601:surgery / Q000628:therapy; D006498:Hepatectomy; D006499:Hepatic Artery; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000628:therapy*; D011169:Portal Vein; D015641:Radiography, Interventional